Glamtush
No Result
View All Result
  • Home
  • News
  • Beauty
  • Business & Brands
  • Entertainment
  • Fashion
  • Features
  • Lifestyle
  • Politics
  • Sports
  • Telenovelas
  • Events
  • Home
  • News
  • Beauty
  • Business & Brands
  • Entertainment
  • Fashion
  • Features
  • Lifestyle
  • Politics
  • Sports
  • Telenovelas
  • Events
No Result
View All Result
Glamtush
No Result
View All Result
Home News

WHO Approves China’s Sinopharm COVID-19 Vaccine

byeditor
May 7, 2021
in News, World News
Reading Time: 2 mins read
Sinopharm COVID-19 Vaccine
Share on FacebookShare on TwitterShare on PinterestShare on WhatsappShare on LinkedinShare on Telegram

WHO Approves China’s Sinopharm COVID-19 Vaccine

 

READ ALSO

Win Big With AGII.NG! ‘Buy & Win’ & ‘Subscribe & Win’ Promos Offer Millions Weekly

BREAKING: NECO Releases 2025 Basic Education Certificate Examination Results

 

 

 

 

The World Health Organization on Friday approved the Sinopharm Covid-19 vaccine for emergency use — the first Chinese jab to receive the WHO’s green light.

The UN health agency signed off on the two-dose vaccine, which is already being deployed in dozens of countries around the world.

The WHO has already given emergency use listing to the vaccines being made by Pfizer-BioNTech, Moderna, Johnson and Johnson, and the AstraZeneca jab being produced at separate sites in India and in South Korea.

“This afternoon, WHO gave emergency use listing to Sinopharm Beijing’s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” WHO chief Tedros Adhanom Ghebreyesus told a news conference.

“The Strategic Advisory Group of Experts on Immunisation, or SAGE, has also reviewed the available data, and recommends the vaccine for adults 18 years and older, with a two-dose schedule.”

An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution, especially those states without an international-standard regulator of their own.

It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries.

The Sinopharm vaccine is already in use in 42 territories around the world, fourth behind AstraZeneca (166), Pfizer-BioNTech (94), and Moderna (46), according to an AFP tally.

Besides China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia, and Seychelles, among others.

A clutch of other vaccines are on the road towards WHO emergency use listing, including a second Sinopharm product being made in Wuhan — the city where coronavirus was first detected.

A decision is expected within days on Sinovac, a second Chinese-made vaccine already being used in 22 countries.

Russia’s Sputnik V vaccine is the next furthest ahead in the process.

 

 

AFP

Related Posts

agii.ng
News

Win Big With AGII.NG! ‘Buy & Win’ & ‘Subscribe & Win’ Promos Offer Millions Weekly

July 11, 2025
2025 Basic Education Certificate Examination
Education

BREAKING: NECO Releases 2025 Basic Education Certificate Examination Results

July 9, 2025
2025 Admissions
Education

JAMB Sets 150 Benchmark For 2025 Admissions

July 9, 2025
MultiChoice Fined ₦766m
News

MultiChoice Fined ₦766m By FG For Privacy Breaches

July 7, 2025
Ladoja
News

Drummers Move To Ladoja’s Home, Signaling Next Olubadan

July 7, 2025
Olubadan
News

How Primate Ayodele Foretold Olubadan’s Demise Two Days Ago In WTN 2025/2026

July 7, 2025
Next Post
Borno Attack

11 IPOB, ESN Members Killed In Imo - Army

LATEST COVER

Priscilla Ojo

GPBN Associates Member

Fidelity Bank

Zenith Bank

WAFCON

WAFCON: Super Falcons Secure $200,000 For Quarter-Final Qualification

July 12, 2025
Galatasaray Bid For Osimhen

Napoli Rejects New €70M Galatasaray Bid For Osimhen

July 12, 2025
Empowering Women

Empowering Women At Work: How Union Bank’s Family-Friendly Revolution Is Setting New Standards

July 11, 2025
agii.ng

Win Big With AGII.NG! ‘Buy & Win’ & ‘Subscribe & Win’ Promos Offer Millions Weekly

July 11, 2025
Empowering Women

Union Bank Responds To High Court Ruling On NICON Investments Limited, Global Fleet And Jimoh Ibrahim Case

July 9, 2025
2025 Basic Education Certificate Examination

BREAKING: NECO Releases 2025 Basic Education Certificate Examination Results

July 9, 2025
ASIS

The Alternative Bank Champions Bold Action For Africa’s Future Ahead Of ASIS 2025 Summit

July 9, 2025
MaWhoo

MaWhoo Takes Her Throne As Spotify EQUAL Africa Ambassador For July

July 9, 2025
Nigerian Idol Season 10

Purp And Raymu To Compete In Nigerian Idol Season 10 Grand Finale

July 9, 2025
2025 Admissions

JAMB Sets 150 Benchmark For 2025 Admissions

July 9, 2025

GLAMTUSH

 

Glamtush publishes the latest trends in fashion, beauty, and lifestyle, as well as those making the fashion world interesting and adorable.

RELEVANT PAGES

  • About Us
  • Advertise
  • Contact Us

REACH OUT

Do you have any news for us? Event Coverage, Press Releases or Adverts? Then reach out to us via glamtush@gmail.com or glamtush15@gmail.com

OFFICE ADDRESS

Lagos, Nigeria

Copyright © 2022 Glamtush

  • About Us
  • Advertise
  • Contact Us
  • Disclaimer
  • Glamtush – Nigeria News, Nigerian Newspapers, Naija News
  • Glamtush – Nigeria News, Nigerian Newspapers, Naija News
  • Terms And Conditions
  • Write for Us

© 2022 Glamtush

No Result
View All Result
  • Home
  • News
  • Beauty
  • Business & Brands
  • Entertainment
  • Fashion
  • Features
  • Lifestyle
  • Politics
  • Sports
  • Telenovelas
  • Events

© 2022 Glamtush